Toluene

Toluene

SCHEMBL6287569

CCCC(=O)O.CCCCCC.Cc1ccccc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.52
HDAC3 O15379 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
AKR1B1 P15121 1/20 0.52
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
CES2 O00748 3/20 0.50
CES1 P23141 3/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
FABP4 P15090 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL585499 0.94 HDAC3 (0.59) FFAR3HDAC3HDAC1HDAC2HDAC8
Hexanoate SCHEMBL9352753 0.92 AKR1B1 (0.64) AKR1B1GPR84PPARGPPARDPPARA
Toluene SCHEMBL3080065 0.92 HDAC3 (0.56) FFAR3HDAC3HDAC1HDAC2HDAC8
Toluene SCHEMBL4678985 0.92 HDAC3 (0.56) FFAR3HDAC3HDAC1HDAC2HDAC8
Hexanoate SCHEMBL28850767 0.90 AKR1B1 (0.61) HDAC3HDAC1HDAC2HDAC8AKR1B1
Palmitic Acid SCHEMBL11331040 0.90 GPR84 (0.65) AKR1B1GPR84PPARGPPARDPPARA
Hexanoate SCHEMBL28176592 0.90 AKR1B1 (0.61) AKR1B1GPR84PPARGPPARDPPARA
Decanoic Acid SCHEMBL18585995 0.90 GPR84 (0.65) AKR1B1GPR84PPARGPPARDPPARA
Octanoic Acid SCHEMBL6273782 0.90 GPR84 (0.65) AKR1B1GPR84PPARGPPARDPPARA
Stearic Acid SCHEMBL8908104 0.90 GPR84 (0.65) AKR1B1GPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969778-B2 DDQ mediated one step dimerization of β-asarone or β-asarone rich Acorus calamus oil in the formation of novel neolignan COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2005-11-29 US disclosed
US-20040049085-A1 DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-03-11 US disclosed
US-20030187306-A1 DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2003-10-02 US disclosed
US-6590127-B1 Formation of alpha-asarone, isoacoramone and 2,4,5-trimethoxycinnamaldehyde in one step process via 2,3-dichloro-5,6-dicyano-1,4-benzoquinone assisted dehydrogenation/oxidation of 2,4,5-trimethoxyphenylpropane COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2003-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040049085-A1 DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan DHPS, PTGES, PTGIS FFAR3 3449/4885HDAC3 3318/4885HDAC1 2621/4885
US-20030187306-A1 DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan DHPS, PTGES, PTGIS FFAR3 3449/4885HDAC3 3318/4885HDAC1 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.